## **Vyvgart Enrollment Form**



Fax Referral To: 1-800-323-2445 Phone: 1-800-378-0695

		nple Steps to Sub		erral
PATIENT INFORMATION				0 1 0 1 1 0 5 1
Patient Name:			DOB:	Gender: Male Female
				ode: vided below)
				ve, you are consenting to receive automated call
				health care. Standard data rates app ly. Message
frequency varies. If unable to cont				
Primary Phone:				
Email:		Last Four c	of SSN:	Primary Language:
				ip to patient:
_				
2 PRESCRIBER INFORMA	TION			
Prescriber's Name:			🗆	
State License #:	NPI#:	DEA #:	Addre	ess:
City, State, ZIP Code:		Group or Hospi	tal:	
Phone: Fax	:	Contact Person:		Contact's Phone:
4 DIAGNOSIS AND CLINIC Needs by Date:			Office Other	÷
Diagnosis (ICD-10):				
G70.00 Myasthenia Gravis wit	hout (acute) exacerl	pation G70.01 M	vasthenia Gravis	with (acute) exacerbation
Other Code: D				
Patient Clinical Information	<u>1:</u>			
Patient to be administered:  CVS Specialty to coordinate skilly of the	illed nursing to prov protocol killed nursing to prov	vide home infusion o vide home administra	_	gravity per home care protocols and provide neous injection
lo this a first dass 0 - Var	¬ мо			
Is this a first dose?  Yes		, daaa0 ☐ MD -tt:-	o with MDO staff	Usanital/Clinia
If yes, where is the patient to be ☐ Home by HC nurse ☐ Other:				— Hospital/Clinic
Specialty Pharmacy to coordina	te nursing for home	e care? 🔲 Yes 🔲 N	10	

**Vyvgart Enrollment Form** 

Please Complete Patient and Prescriber Information									
Patient Name:									
				D:					
Patient Clinical In									
Allergies:		<u> </u>	Weight:	lb/kg Height:	in/cm				
5 PRESCRIPTION	INFOR	MATION			·				
MEDICATION	STRI	ENGTH	DOSE &	DIRECTIONS	QUANTITY/REFILLS				
☐ Vyvgart (Intravenous)	400 mg. (20 mg/	/20 mL	☐ Infuse IV 10 mg/kg (Dose = mg) weekly for 4 weeks (1 cycle). Infuse over 1 hour.  ☐ Infuse mg/kg (Dose = mg) weekly for weeks. (1 cycle) Infuse over hour(s).  In patients weighing 120 kg or more, the recommended dose is 1200 mg per infusion.  According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start		Initiation of Last Cycle Date:  Quantity Sufficient of vials (1 cycle)  Number of refills (Treatment cycles) authorized:				
☐ Vyvgart Hytrulo (Subcutaneous)	1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per 5.6 mL		of the previous treatment cycle has not been established.  Administer 4 weekly injections (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per week) subcutaneously over approximately 30-90 seconds.  Administer subsequent treatment cycles according to clinical evaluation. The safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.		Initiation of Last Cycle Date:  Quantity Sufficient of vials (1 cycle)  Number of refills (Treatment cycles) authorized:  *1 cycle = 4 weekly injections				
<b>Nursing Medica</b>	tions <u>C</u>	omplete i	tems below, required for H	ome Infusion					
MEDICATION/SU	PPLIES	<b>ROUTE</b>	DOSE/STRENC	TH/DIRECTIONS	QUANTITY/REFILLS				
□ 0.9% Sodium Chloride N/A		Use 0.9% Sodium Chloride Injection, USP, as a diluent to make a total volume to be administered of 125 mL		Quantity Sufficient Refills: PRN					
Catheter PIV PORT PICC		Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV – NS 5 mL PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 mL, and/or 10 mL sterile saline to access port a cath		Quantity Sufficient Refills: PRN					
☐ Epinephrine  **nursing requires** ☐ SC ☐ Patient is interested in patient support programs		Adult 1:1000, 0.3 mL (>30 kg/>66 lbs)  PRN severe allergic reaction – Call 911  May repeat in 5-15 minutes as needed  STAMP SIGNATURE NOT ALLOWED  Ancillary supplies and kits p		Quantity: Refills: provided as needed for administration					
6 PRESCRIBER SI	IGNATU	IRE REOL	IRED (STAMP SIGNATU	RE NOT ALLOWED)	,				
"Dispense As Written" / Brand	l Medically Ne	cessary / Do No	t Substitute / No Substitution / DAW / May	Substitute / Product Selection Permitted /					
May Not Substitute Prescriber's Signature:				titution Permissible scriber's Signature:	Date:				
				-					
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescription									

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private he alth information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS. Health and/or one of its affiliates.